| Clinical Characteristics | Total, n (%) | Missing, n (%) | Hazard ratio* (95% CI) | 3-month survival (%) | 6-month survival (%) | 12-month survival (%) | P value** |
|---|
| Gender |
| Male | 60 (87.0) | 0 (0) | Reference | 45.0 | 33.3 | 16.7 | 0.520 |
| Female | 9 (13.0) | | 0.79 (0.39, 1.61) | 66.7 | 44.4 | 22.2 | |
| Age group (years) | | | | | | | |
| ≤ 60 years | 50 (72.5) | 0 (0) | Reference | 52.0 | 38.0 | 22.0 | 0.036 |
| > 60 years | 19 (27.5) | | 1.78 (1.03, 3.08) | 36.8 | 26.3 | 5.3 | |
| Karnofskys Performance Status |
| Good | 17 (24.7) | 0 (0) | Reference | 82.4 | 70.6 | 41.2 | 0.003 |
| Moderate | 25 (36.2) | | 2.29 (1.15, 4.54) | 48.0 | 28.0 | 12.0 | |
| Poor | 27 (39.1) | | 3.16 (1.63, 6.15) | 25.9 | 18.5 | 7.4 | |
| Cirrhosis |
| No | 21 (30.4) | 7 (10.2) | Reference | 66.7 | 47.6 | 23.8 | 0.024 |
| Yes | 41 (59.4) | | 1.95 (1.08, 3.51) | 39.0 | 29.3 | 17.1 | |
| Ascites | | | | | | | |
| No | 33 (47.8) | 10 (14.5) | Reference | 66.7 | 51.5 | 27.3 | 0.001 |
| Yes | 26 (37.7) | | 2.44 (1.39, 4.28) | 26.9 | 15.4 | 7.7 | |
| Total bilirubin (mg/dL) |
| < 2.0 | 55 (79.7) | 1 (1.5) | Reference | 56.4 | 43.6 | 21.8 | < 0.001 |
| 2.0–3.0 | 5 (7.2) | | 2.75 (1.06, 7.15) | 20.0 | 0 | 0 | |
| > 3.0 | 8 (11.6) | | 11.25 (4.39, 28.86) | 0 | 0 | 0 | |
| Serum albumin (mg/dL) |
| > 3.5 | 25 (36.2) | 1 (1.5) | Reference | 68.0 | 56.0 | 24.0 | 0.056 |
| 2.8–3.5 | 26 (37.7) | | 1.38 (0.78, 2.45) | 30.8 | 23.1 | 19.2 | |
| < 2.8 | 17 (24.6) | | 2.17 (1.14, 4.14) | 41.2 | 23.5 | 5.9 | |
| Number of primary tumor |
| Single tumor | 14 (20.3) | 2 (2.9) | Reference | 71.4 | 50.0 | 35.7 | 0.018 |
| Multiple tumors | 53 (76.8) | | 2.20 (1.13, 4.29) | 43.4 | 32.1 | 13.2 | |
| Portal vein involvement | | | | | | | |
| No | 28 (40.6) | 11 (15.9) | Reference | 71.4 | 50.0 | 25.0 | 0.196 |
| Yes | 30 (43.5) | | 1.43 (0.83, 2.45) | 33.3 | 26.7 | 16.7 | |
| Visceral organ metastasis |
| No | 35 (50.7) | 2 (2.9) | Reference | 65.7 | 51.4 | 25.7 | 0.017 |
| Yes | 32 (46.4) | | 1.35 (1.05, 1.73) | 31.3 | 18.8 | 9.4 | |
| Number of vertebral columns involved |
| 1 | 30 (43.5) | 3 (4.4) | Reference | 53.3 | 40.0 | 20.0 | 0.751 |
| 2 | 19 (27.5) | | 0.95 (0.52, 1.73) | 57.9 | 36.8 | 15.8 | |
| ≥ 3 | 17 (24.6) | | 1.21 (0.66, 2.22) | 35.3 | 29.4 | 17.7 | |
| Number of extra spinal bone metastases |
| 0 | 32 (46.4) | 7 (10.2) | Reference | 59.4 | 43.8 | 25.0 | 0.256 |
| 1–2 | 21 (30.4) | | 1.52 (0.86, 2.69) | 42.9 | 33.3 | 14.3 | |
| ≥ 3 | 9 (13.0) | | 1.64 (0.74, 3.63) | 33.3 | 22.2 | 11.1 | |
- Abbreviations: CI confidence interval
- *Hazard ratio from univariable Cox’s proportional hazard regression
- **P value from log-rank test
